A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease
Status:
Not yet recruiting
Trial end date:
2026-08-01
Target enrollment:
Participant gender:
Summary
VT-10201 is an Open-label, Phase 1b, Single-ascending Dose Study That Will Evaluate the
Safety of VERVE-102 Administered to Patients With Heterozygous Familial Hypercholesterolemia
(HeFH) or Premature Coronary Artery Disease (CAD) Who Require Additional Lowering of LDL-C.
VERVE-102 Uses Base-editing Technology Designed to Disrupt the Expression of the PCSK9 Gene
in the Liver and Lower Circulating PCSK9 and LDL-C. This Study is Designed to Determine the
Safety and Pharmacodynamic Profile of VERVE-102 in This Patient Population.